The 5 Best-Selling Drugs of 2017
We spent $328.6 billion on prescription drugs in 2016 -- and that's just the United States. The amount will no doubt be higher when the books are closed on 2017.
Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG), Roche (NASDAQOTH: RHHBY), and Pfizer (NYSE: PFE). Some of these drugs could make even more money in 2018, but others are likely to drop off the list. Here are the top five best-selling drugs in the world so far in 2017.
Image source: Getty Images.
Source: Fool.com
AbbVie Inc. Aktie
177,62 €
1,06 %
Überwältigendes Buy-Interesse für AbbVie Inc.: 33 Buy-Einschätzungen ohne eine einzige Sell-Einschätzung.
Ein positives, aber moderates Potenzial für AbbVie Inc. mit einem Kursziel von 180 € im Vergleich zu 177.62 €.
